NASDAQ: SNDXSyndax Pharmaceuticals Inc Stock
$11.54+0.49 (+4.43%)
Updated Apr 17, 2025
SNDX Price
$11.54
Fair Value Price
$1.79
Market Cap
$992.72M
52 Week Low
$9.66
52 Week High
$25.07
P/E
-3.1x
P/B
3.45x
P/S
47.8x
PEG
N/A
Dividend Yield
N/A
Revenue
$23.68M
Earnings
-$318.76M
Gross Margin
96.5%
Operating Margin
-1,325.29%
Profit Margin
-1,346.1%
Debt to Equity
1.52
Operating Cash Flow
-$275M
Beta
0.99
Next Earnings
May 6, 2025
Ex-Dividend
N/A
Next Dividend
N/A
SNDX Overview
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML); and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD). The company is also developing Entinostat. It also has collaborative research and development agreement with National Cancer Institute; a clinical trial agreement with Eastern Cooperative Oncology Group; and a license agreement with Kyowa Hakko Kirin Co., Ltd. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.Massachusetts.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine SNDX's potential to beat the market
FStrong Sell
- Stocks with a Zen Rating of Strong Sell (F) had an average loss of -8.02% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
SNDX
Ranked#454 of 463
Ranked#454 of 463
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $2.61 | A | |
| $7.75 | A | |
| $16.85 | A |
Be the first to know about important SNDX news, forecast changes, insider trades & much more!
SNDX News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how SNDX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
SNDX ($11.54) is overvalued by 544.38% relative to our estimate of its Fair Value price of $1.79 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
SNDX ($11.54) is not significantly undervalued (544.38%) relative to our estimate of its Fair Value price of $1.79 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
SNDX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more SNDX due diligence checks available for Premium users.
Valuation
SNDX fair value
Fair Value of SNDX stock based on Discounted Cash Flow (DCF)
Price
$11.54
Fair Value
$1.79
Overvalued by
544.38%
SNDX ($11.54) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
SNDX ($11.54) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
SNDX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
SNDX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-3.1x
Industry
-177.72x
Market
27.98x
SNDX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
3.45x
Industry
4.05x
SNDX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
SNDX's financial health
Profit margin
Revenue
$7.7M
Net Income
-$94.2M
Profit Margin
-1,226.2%
SNDX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
SNDX's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$724.8M
Liabilities
$436.7M
Debt to equity
1.52
SNDX's short-term assets ($603.06M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
SNDX's short-term assets ($603.06M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
SNDX's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
SNDX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$57.4M
Investing
-$269.0M
Financing
$347.4M
SNDX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
SNDX vs Biotech Stocks
Syndax Pharmaceuticals Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.